-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that EIR Biopharma is a pre-clinical biotechnology company dedicated to developing therapies for ophthalmic diseases introduced through authorization. The company withdrew its IPO plan on Monday. It submitted an application in February 2026 to sell 3.8 million shares at a price of 4 to 5 US dollars each, raising 17 million US dollars.
Share
Listen to the news
The Zhitong Finance App learned that EIR Biopharma is a pre-clinical biotechnology company dedicated to developing therapies for ophthalmic diseases introduced through authorization. The company withdrew its IPO plan on Monday. It submitted an application in February 2026 to sell 3.8 million shares at a price of 4 to 5 US dollars each, raising 17 million US dollars.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending